Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O....
-
Upload
raymond-carson -
Category
Documents
-
view
218 -
download
0
Transcript of Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O....
![Page 1: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/1.jpg)
Anxiety and DepressionComparison of the Serotonergic Antidepressants
Douglas L. Geenens, D.O.Faculty in Psychopharmacology, Menninger
Associate Clinical Professor, University of Health Sciences, College of Osteopathic Medicine
Assistant Clinical Professor, University of Missouri at Kansas City School of Medicine
Adjunct Clinical Professor, University of Kansas School of Medicine
![Page 2: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/2.jpg)
Variables to Compare
• Research and Development
• Indications
• Efficacy
• Structure
• Pharmacodynamics*
• Pharmacokinetics*
• Side-effects*
• Dosing Preparations
• Cost Considerations
![Page 3: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/3.jpg)
Currently Available in U.S.A.• fluoxetine (Prozac) 1988• sertraline (Zoloft) 1992• paroxetine (Paxil) 1993
• fluvoxamine (Luvox) 1994• citalopram (Celexa) 1998
• s-citalopram (Lexapro) 2002
• venlafaxine (Effexor) 1995• nefazodone (Serzone) 1996
• mirtazepine (Remeron) 1997
![Page 4: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/4.jpg)
FDA Indications• OCD
• Major Depression
• Geriatric Depression
• Panic Disorder
• Bulimia
• Social Phobia
• OCD in children (ages 6-18)
• PTSD
• PMDD
• GAD
• All, except citalopram (s)
• All, except Luvox
• fluoxetine
• sertraline, paroxetine
• fluoxetine
• paroxetine
• sertraline, fluvoxamine
• sertraline, paroxetine
• fluoxetine, sertraline
• venlafaxine, paroxetine
![Page 5: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/5.jpg)
Chemical Structure• These compounds are structurally unrelated.
• This may account for the differential response we see in some patients with one antidepressant vs. another.
• Rationale for differential response may be related to different morphology of the serotonin transport protein.
![Page 6: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/6.jpg)
Fluvoxamine
F3C C CH2 CH2 CH2 CH2 O CH3
N
O CH2 CH2 NH2
Paroxetine
N
O
OO
CH2
Fluoxetine
O CH
CH2 CH2 NCH3
H
Sertraline
HNCH3
Cl
Cl
SSRI Structures
Celexa Package Insert, Forest Laboratories, Inc.Physicians’ Desk Reference. 1998.
CitalopramS-citalopram F
O
NC
CH2CH2CH2N(CH3)2·HBr
![Page 7: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/7.jpg)
Switch Rates of SSRIsn = 573
• Time course– one month
• 13%
– three months• 23%
– six months• 32%
– nine months• 40%
• Percentage of patients staying on initial drug– fluoxetine
• 50%
– sertraline• 43%
– paroxetine• 41%
Kroenke et al., “Similar Effectiveness of Paroxetine, Fluoxetine, and Sertraline in Primary Care, JAMA, Dec 19, 2001, Vol. 286, No. 23
![Page 8: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/8.jpg)
Efficacy
• All more effective than placebo (60-79%).
• All have similar efficacy as TCAs (62-68%), when using 50% reduction in HAM-D scores (response).
• Dual-mechanism antidepressants may show better efficacy when remission scores are used (HAM-D < 8).
• All prevent relapse in depressed patients vs. placebo (20% vs. 50%).
![Page 9: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/9.jpg)
Pharmacodynamics
• Similarities
• All inhibit neuronal reuptake of 5-HT.
• Differences
• Variable affinity for other neuro-receptors.
• Variable potency at blocking 5-HT at therapeutic doses.
• Dose-response curves vary.
![Page 10: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/10.jpg)
Dose-response Curves
Dose
Res
pons
e
Celexa
Oth
er S
SRI’
s
![Page 11: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/11.jpg)
% Blockade of 5-HT
• 80%
• 70%
• 60%
• fluoxetine 20mg• sertraline 50mg• paroxetine 20mg
• fluvoxamine 150mg
• citalopram 40mg
Preskorn 1998
![Page 12: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/12.jpg)
Guidelines for Interpreting Ki (nmol/L) values
• <10– very potent
• 10-1000– moderately potent
• >1000– likely to have little clinical effect
![Page 13: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/13.jpg)
Potency and Selectivity of the SSRIs
Owens et al., 2001
Uptake InhibitionKi (nmol/L)
5-HT Selectivity
5-HT NE DA NE/5-HT Ratio
Drug
2.5 6,514 >100,000 2,606Escitalopram
9.6 5,029 >100,000 524Citalopram
2.8 925 315 330Sertraline
5.7 599 5,960 105Fluoxetine
0.34 156 963 459Paroxetine
Human Monoamine Uptake Inhibition
A lower Ki reflects greater potencyA higher selectivity ratio [Ki (nmol/L) NE/ Ki (nmol/L) 5-HT] reflects greater specificity
lessselective
![Page 14: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/14.jpg)
Possible Clinical Consequences of 5-HT Reuptake Blockade
• Antidepressant effect
• Gastrointestinal disturbances
• Anxiety (dose-dependent)
• Sexual dysfunction
• Impaired cognition
![Page 15: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/15.jpg)
Serotonin
0
20
40
60
80
100
120
140
fluox
etine
sertr
aline
paro
xetin
e
fluvo
xam
ine
citalo
pram
s-cita
lopr
am
potency
Richelson E, Synaptic Effects of Antidepressants, Journal of Clinical Psychopharmacology,Vol. 16, No3, Suppl. 2, June 1996
![Page 16: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/16.jpg)
Possible Clinical Consequences of NE Reuptake Blockade
• Antidepressant effect
• Tremors
• Tachycardia
• Enhanced cognition
![Page 17: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/17.jpg)
Norepinephrine
0
20
40
60
80
100
120
fluox
etine
sertr
aline
paro
xetin
e
fluvo
xam
ine
citalo
pram
s-cita
lopr
am dmi
potency
Richelson E, Synaptic Effects of Antidepressants, Journal of Clinical Psychopharmacology,Vol. 16, No3, Suppl. 2, June 1996
![Page 18: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/18.jpg)
Selectivity for 5-HT vs. NE Transporter
0100200300400500600700800900
fluox
etine
sertr
aline
paro
xetin
e
fluvo
xam
ine
citalo
pram
s-cita
lopr
am
selectivity
Richelson E, Synaptic Effects of Antidepressants, Journal of Clinical Psychopharmacology,Vol. 16, No3, Suppl. 2, June 1996
![Page 19: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/19.jpg)
SelectivityEscitalopramCitalopramSertralineFluoxetineParoxetine
Ki (NE) / Ki (5-HT)
100100010000
less selective
more selective
Owens et al., 2001
![Page 20: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/20.jpg)
Possible Clinical Consequences of DA Reuptake Blockade
• Psychomotor activation
• Psychosis
• Antiparkinsonian effects
• Enhanced cognition
![Page 21: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/21.jpg)
Dopamine
0
0.2
0.4
0.6
0.8
1
1.2
fluox
etine
sertr
aline
paro
xetin
e
fluvo
xam
ine
citalo
pram
s-cita
lopr
am
amph
etam
ine
potency
Richelson E, Synaptic Effects of Antidepressants, Journal of Clinical Psychopharmacology,Vol. 16, No3, Suppl. 2, June 1996
![Page 22: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/22.jpg)
Possible Clinical Consequences of Muscarinic Blockade
• Blurred vision
• Dry mouth
• Sinus tachycardia
• Constipation
• Urinary retention
• Memory dysfunction
![Page 23: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/23.jpg)
Acetylcholine
0
1
2
3
4
5
6
fluox
etin
e
sert
ralin
e
parox
etin
e
fluvo
xam
ine
cital
opra
m
s-cita
lopra
m ami
dmi
potency
Richelson E, Synaptic Effects of Antidepressants, Journal of Clinical Psychopharmacology,Vol. 16, No3, Suppl. 2, June, 1996
![Page 24: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/24.jpg)
SSRI Effects on Vigilance and CognitionA Placebo-controlled Comparison of Sertraline and Paroxetine
• N = 24, nondepressed volunteers
• double-blind, crossover, prospective
• measures of vigilance, memory, attention span
• Zoloft outperformed Paxil in all measures (p<.05). Why?
Schmitt et al, NCDEU Annual Meeting, 1999
![Page 25: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/25.jpg)
Possible Clinical Consequences of Histamine (H1) Blockade
• Sedation and drowsiness
• Weight gain
• Hypotension
![Page 26: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/26.jpg)
Histamine (H1)
0102030405060708090
100
fluox
etine
sertr
aline
paro
xetin
eflu
voxa
min
ecit
alopr
ams-c
italo
pram
amiti
ptyl
ineBen
adry
l
potency
Richelson E, Synaptic Effects of Antidepressants, Journal of Clinical Psychopharmacology,Vol. 16, No3, Suppl. 2, June, 1996
![Page 27: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/27.jpg)
0
500
1000
1500
2000
escitalopram citalopram R-citalopram
Ki (nM)
Histamine (H1)-Receptor Binding
lower
affinity
Owens et al., 2001
![Page 28: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/28.jpg)
Medication
02
46
810
1214
161820
5-HT NE DA ACH H1
potency
![Page 29: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/29.jpg)
fluoxetine (Prozac)
0
1
2
3
4
5
6
7
8
9
5-HT NE DA ACH H1
potency
Richelson E, Synaptic Effects of Antidepressants, Journal of Clinical Psychopharmacology,Vol. 16, No3, Suppl. 2, June, 1996
![Page 30: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/30.jpg)
sertraline (Zoloft)
0
5
10
15
20
25
30
5-HT NE DA ACH H1
potency
Richelson E, Synaptic Effects of Antidepressants, Journal of Clinical Psychopharmacology,Vol. 16, No3, Suppl. 2, June, 1996
![Page 31: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/31.jpg)
paroxetine (Paxil)
0
20
40
60
80
100
120
140
5-HT NE DA ACH H1
potency
Richelson E, Synaptic Effects of Antidepressants, Journal of Clinical Psychopharmacology,Vol. 16, No3, Suppl. 2, June, 1996
![Page 32: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/32.jpg)
fluvoxamine (Luvox)
0
2
4
6
8
10
12
14
5-HT NE DA ACH H1
potency
Richelson E, Synaptic Effects of Antidepressants, Journal of Clinical Psychopharmacology,Vol. 16, No3, Suppl. 2, June, 1996
![Page 33: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/33.jpg)
venlafaxine (Effexor)
0
0.5
1
1.5
2
2.5
3
5-HT NE DA ACH H1
potency
Richelson E, Synaptic Effects of Antidepressants, Journal of Clinical Psychopharmacology,Vol. 16, No3, Suppl. 2, June, 1996
![Page 34: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/34.jpg)
nefazodone (Serzone)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
5-HT NE DA ACH H1
potency
Richelson E, Synaptic Effects of Antidepressants, Journal of Clinical Psychopharmacology,Vol. 16, No3, Suppl. 2, June, 1996
![Page 35: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/35.jpg)
citalopram (Celexa)
00.2
0.40.6
0.81
1.21.4
1.61.8
2
5-HT NE DA ACH H1
potency
Richelson E, Synaptic Effects of Antidepressants, Journal of Clinical Psychopharmacology,Vol. 16, No3, Suppl. 2, June, 1996
![Page 36: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/36.jpg)
s-citalopram (Lexapro)
0
5
10
15
20
25
30
5-HT NE DA ACH H1
East
![Page 37: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/37.jpg)
Summaryof pharmacodynamic differences
• Dose-response curves
– citalopram is linear
• Serotonergic reuptake blockade
– paroxetine is the most potent
• Selectivity
– citalopram is the most selective
• Dopamine reuptake blockade
– sertraline is the most potent
• Anticholinergic effect
– paroxetine is the most potent
![Page 38: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/38.jpg)
Pharmacokinetics of the SSRIs
• Similarities
• All require hepatic oxidative enzymes for metabolism.
• All have variable affinity for blocking the p-450 isoenzymes.
• Differences
• Half-lives vary.
• Different P-450 isoenzymes are inhibited by the SSRIs.
![Page 39: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/39.jpg)
Issues to Consider in the Elderly
• Burden on hepatic functioning.
• Potential for drug-drug interactions.
• Side-effects
![Page 40: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/40.jpg)
Pharmacokinetic Parameters of the SSRIs
Half-life (hours) 27-32 35 96-386 21 26
Protein bound (%) 56% 80% 94% 95% 98%
Absorption altered No No No No Yes by fast or fed status
Linear kinetics Yes Yes No No Yes
Dose range (mg/day) 10-20 20-60 20-80 10-50 50-200for MDD
Escitalopram Citalopram Fluoxetine Paroxetine Sertraline
Van Harten, 1993; Preskorn, 1997; Preskorn, 1993; Physician’s Desk Reference, 2002; Forest Laboratories, data on file, 2002
![Page 41: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/41.jpg)
Half-lives of the SSRIs
0102030405060708090
fluox
etin
e
sert
ralin
e
parox
etin
e
fluvo
xam
ine
cital
opra
m
s-cita
lopra
m
hours
![Page 42: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/42.jpg)
P-450 Enzymes and the SSRIs (at least moderate activity >50%)• Similarities
• P-450 enzymes metabolize the SSRIs.
• Some SSRIs inhibit some P-450 enzymes.
• Differences• fluoxetine: 2D6, 2C9/10,
2C19
• sertraline: none
• paroxetine: 2D6
• fluvoxamine: 1A2, 2C19, 3A3/4
• citalopram (s): none
• venlafaxine, bupropion, mirtazepine: none
Preskorn, 1998
![Page 43: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/43.jpg)
CYP2D6
• Substrates
• Analgesics• Antidepressants• Antipsychotics• Cardiovascular preps• Amphetamine• Diphenhydramine
• Inhibitors
• Quinidine• Paroxetine*• Fluoxetine*
![Page 44: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/44.jpg)
CYP2D6 Inhibition in Vitro
00.05
0.10.15
0.20.25
0.30.35
0.40.45
0.5fl
uoxe
tine
sert
rali
ne
paro
xeti
ne
fluv
oxam
ine
cita
lopr
am
potencynorfluoxetine
Preskorn, 1998
![Page 45: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/45.jpg)
CYP3A4
• Substrates
• Antidepressants
• Antihistamines
• Cardiovascular preps
• Sedative-hypnotics
• Corticosteroids
• Carbamazepine
• Terfenadine
• Inhibitors
• Ketoconazole
• Itraconazole
• Erythromycin
• Grapefruit juice
• nefazodone*
• fluvoxamine*
• norfluoxetine*
![Page 46: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/46.jpg)
CYP3A4 Inhibition in Vitro
0
0.002
0.004
0.006
0.008
0.01
0.012fl
uoxe
tine
sert
rali
ne
paro
xeti
ne
fluv
oxam
ine
cita
lopr
am
potencymetabolites
Preskorn, 1998
![Page 47: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/47.jpg)
CYP1A2
• Substrates
• Caffeine• Clozapine• Antidepressants• Theophylline• R-warfarin
• Inhibitors
• Fluvoxamine*
![Page 48: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/48.jpg)
CYP1A2 Inhibition in Vitro
00.05
0.10.15
0.20.25
0.30.35
0.40.45
0.5fl
uoxe
tine
sert
rali
ne
paro
xeti
ne
fluv
oxam
ine
cita
lopr
am
potency
Preskorn, 1998
![Page 49: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/49.jpg)
Active Metabolites and the SSRIs
• Active Metabolites
• fluoxetine (1-4 days) norfluoxetine (7-15 days)
• No Active Metabolites
• sertraline,• paroxetine,• fluvoxamine,• citalopram• s-citalopram
![Page 50: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/50.jpg)
Auto-inhibition of Metabolism and the SSRIs
• Auto-inhibition
• fluoxetine• paroxetine• fluvoxamine
• No Auto-inhibition
• sertraline• citalopram• s-citalopram
![Page 51: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/51.jpg)
Sertraline vs. Paroxetinen=176 n=177
• diarrhea • constipation• fatigue• decreased libido• urinary retention• weight gain• tachycardia• increased sleep
p<.05, APA 1998
![Page 52: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/52.jpg)
Sexual Dysfunction
• Clinical rates approximate 50% of patients.
• Paroxetine appears to cause higher rates of sexual dysfunction in most head to head studies. (potency and anti-ACH effects)
• Paroxetine may be the d.o.c. for premature ejaculation. (prolongs orgasmic latency 8 fold)
![Page 53: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/53.jpg)
Rates of Sexual DysfunctionMontejo et al, 2001
• N = 1022– Celexa (28.7)
– Paxil (23.4)
– Effexor (159.5)
– Zoloft (90.4)
– Luvox (115.7)
– Prozac (24.5)
– Remeron (37.7)
– Serzone (324.6)
– 72.7%
– 70.7%
– 67.3%
– 62.9%
– 62.3%
– 57.7%
– 24.4%
– 8.0%
![Page 54: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/54.jpg)
Dosing Preparations
• Similarities
• All available in tablets (fluoxetine 10 mg only).
• Differences
• Liquid preparations:– fluoxetine (mint)
– paroxetine (orange)
– sertraline (mint)
– citalopram (mint)
• Capsule preparation: fluoxetine
• Sustained release: paroxetine
![Page 55: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/55.jpg)
Cost Considerations• fluoxetine:
– 10 mg scored tab, 10 and 20 mg pulvules are the same cost – 40 mg dose offers no cost savings.– 90 mg weekly is competitive – Generic preparation available
• sertraline: 25, 50, and 100 mg tablets are the same cost. All are scored.
• paroxetine: 10, 20, 30, 40 mg tablets are the same cost. 10 and 20 mg tablet are scored. 12.5, 25, 37.5 CR are the same cost.
• fluvoxamine: 25, 50, and 100 mg tabs. 50 and 100 mg tablets are scored.
• citalopram: 20 and 40 mg tablets are the same cost. Both doses are scored.
• S-citalopram: 10 and 20 mg tabs. Both doses are scored.
![Page 56: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/56.jpg)
fluoxetine (Prozac)• Most US research across the diagnostic spectrum.
• Indicated for Bulimia, Geriatric Depression, and PMDD, plus two others.
• Longest half-life.
• Relatively fewer side effects.
• Potential for drug-drug interactions, especially psychiatric (2D6) is a concern.
• At doses below 10 mg, inexpensive.
• At higher doses, cost is incrementally higher. Some cost savings with weekly dose and generic prep.
• Available in a liquid dosing form (mint).
![Page 57: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/57.jpg)
sertraline (Zoloft)
• Six indications, including PTSD, PMDD, and OCD in children.
• Most dopamine transporter blocking potency.
• Intermediate half-life with no active metabolites.
• Linear pharmacokinetics.
• Lower potential for drug-drug interactions.
• Relatively fewer side-effects (watch for GI).
• At lower doses, may be the most cost effective.
• Available in liquid dosing form (mint).
![Page 58: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/58.jpg)
paroxetine (Paxil)• Indicated for Social Phobia, plus five others.
• Significantly more anti-ACH affinity, thus more anti-ACH side effects.
• Intermediate half-life, no active metabolites.
• Potential for drug-drug interactions, especially psychiatric (2D6) is of concern.
• Worst side effect profile and highest rates of sexual dysfunction. May be d.o.c. for premature ejaculation.
• Liquid preparation available (orange).
• At higher doses, may be the most cost effective.
• Available in sustained release form.
![Page 59: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/59.jpg)
fluvoxamine (Luvox)
• Two indications, includes OCD in children.• Intermediate half-life, no active metabolites.
• Side-effect profile is relatively worse.• Dosing often requires titration.
• Highest potential for drug-drug interactions.• May be inexpensive at lower doses, and expensive
at higher doses.
![Page 60: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/60.jpg)
citalopram (Celexa)• One indication, depression.
• Low potency at 5-HT reuptake blockade (60% at 40mg).
• Linear dose-response curve.
• Intermediate half-life. No active metabolites.
• Linear pharmacokinetics.
• Fewer side effects at low doses.
• Lower potential for drug-drug interactions.
• Cost effective throughout dosage range (40mg).
• Liquid preparation available (mint).
![Page 61: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/61.jpg)
S-citalopram (Lexapro)
• Most selective of the SSRIs• Flat-dose response curve
• Potency of blocking 5-HT is comparable to sertraline
![Page 62: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/62.jpg)
Beyond the SSRIs
• Effexor
• Serzone
• Remeron
• 5-HT, NE, and DA reuptake block.
• 5-HT2 block; weaker 5-HT and NE reuptake block.
• 5-HT and NE increase (via alpha 2 antagonism); 5-HT2 and 5-HT3 block.
![Page 63: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/63.jpg)
Anxiety and DepressionComparison of the Serotonergic Antidepressants
Douglas L. Geenens, D.O.Faculty in Psychopharmacology, Menninger
Associate Clinical Professor, UHSCOM
Assistant Clinical Professor, UMKC
Adjunct Clinical Professor, KUMC
![Page 64: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/64.jpg)
![Page 65: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/65.jpg)
![Page 66: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/66.jpg)
![Page 67: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/67.jpg)
![Page 68: Anxiety and Depression Comparison of the Serotonergic Antidepressants Douglas L. Geenens, D.O. Faculty in Psychopharmacology, Menninger Associate Clinical.](https://reader033.fdocuments.us/reader033/viewer/2022051315/56649e845503460f94b85888/html5/thumbnails/68.jpg)